Pushing the limits of targeted therapy in chronic myeloid leukaemia
T O'hare, MS Zabriskie, AM Eiring… - Nature Reviews …, 2012 - nature.com
Tyrosine kinase inhibitor (TKI) therapy targeting the BCR-ABL1 kinase is effective against
chronic myeloid leukaemia (CML), but is not curative for most patients. Minimal residual …
chronic myeloid leukaemia (CML), but is not curative for most patients. Minimal residual …
Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles
P Di Gion, F Kanefendt, A Lindauer, M Scheffler… - Clinical …, 2011 - Springer
Pyrimidine (imatinib, dasatinib, nilotinib and pazopanib), pyridine (sorafenib) and pyrrole
(sunitinib) tyrosine kinase inhibitors (TKIs) are multi-targeted TKIs with high activity towards …
(sunitinib) tyrosine kinase inhibitors (TKIs) are multi-targeted TKIs with high activity towards …
Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling
A detailed understanding of the mechanisms by which tumors acquire resistance to targeted
anticancer agents should speed the development of treatment strategies with lasting clinical …
anticancer agents should speed the development of treatment strategies with lasting clinical …
The high cost of cancer drugs and what we can do about it
M Siddiqui, SV Rajkumar - Mayo Clinic Proceedings, 2012 - mayoclinicproceedings.org
Last year, ipilimumab (Yervoy; Bristol-Myers Squibb, New York, NY) was approved by the
Food and Drug Administration (FDA) for the treatment of metastatic melanoma. The benefit …
Food and Drug Administration (FDA) for the treatment of metastatic melanoma. The benefit …
Interaction of the efflux transporters ABCB1 and ABCG2 with imatinib, nilotinib, and dasatinib
The efflux transporters adenosine triphosphate (ATP)‐binding cassette (ABC) B1 and
ABCG2 have been demonstrated to interact with the tyrosine kinase inhibitors (TKIs) …
ABCG2 have been demonstrated to interact with the tyrosine kinase inhibitors (TKIs) …
[HTML][HTML] Influence of enzyme and transporter polymorphisms on trough imatinib concentration and clinical response in chronic myeloid leukemia patients
Background This study explored the impact of genetic polymorphisms in cytochrome P450
(CYP) enzymes and transporters on the plasma trough concentration of imatinib mesylate …
(CYP) enzymes and transporters on the plasma trough concentration of imatinib mesylate …
Emerging therapeutic strategies for targeting chronic myeloid leukemia stem cells
Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder. Current targeted
therapies designed to inhibit the tyrosine kinase activity of the BCR‐ABL oncoprotein have …
therapies designed to inhibit the tyrosine kinase activity of the BCR‐ABL oncoprotein have …
Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemia
EQ Wu, A Guerin, AP Yu, VK Bollu, A Guo… - … medical research and …, 2010 - Taylor & Francis
Objective: To compare healthcare resource utilization, costs, and treatment adherence
associated with dasatinib versus nilotinib treatment as second-line therapies in chronic …
associated with dasatinib versus nilotinib treatment as second-line therapies in chronic …
[HTML][HTML] Variation of cost among anti-cancer drugs available in Indian market
BP Kolasani, DC Malathi… - Journal of clinical and …, 2016 - ncbi.nlm.nih.gov
Aim The aim of the present observational study was to analyse the price variations of anti-
cancer drugs available in India. Materials and Methods The cost of a particular anti-cancer …
cancer drugs available in India. Materials and Methods The cost of a particular anti-cancer …
Targeting hypoxia-induced tumor stemness by activating pathogen-induced stem cell niche defense
Tumor hypoxia and oxidative stress reprograms cancer stem cells (CSCs) to a highly
aggressive and inflammatory phenotypic state of tumor stemness. Previously, we …
aggressive and inflammatory phenotypic state of tumor stemness. Previously, we …